scispace - formally typeset
Open AccessJournal ArticleDOI

The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM

Reads0
Chats0
TLDR
A marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping are notable.
Abstract
The American Joint Committee on Cancer and the International Union for Cancer Control update the tumor-node-metastasis (TNM) cancer staging system periodically. The most recent revision is the 7th edition, effective for cancers diagnosed on or after January 1, 2010. This editorial summarizes the background of the current revision and outlines the major issues revised. Most notable are the marked increase in the use of international datasets for more highly evidenced-based changes in staging, and the enhanced use of nonanatomic prognostic factors in defining the stage grouping. The future of cancer staging lies in the use of enhanced registry data standards to support personalization of cancer care through cancer outcome prediction models and nomograms.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.

TL;DR: Targeting compensatory metabolic reprogramming of glutamine metabolism in sorafenib-resistant HCC by inhibiting PPARδ constitutes a potential therapeutic strategy for overcoming sorafinib-resistance in HCC.
Journal ArticleDOI

Prognosis according to histochemical analysis of liver metastases removed at liver resection

TL;DR: The aim of this study was to examine the immunological architecture of colorectal liver metastases and its impact on patient survival.
Journal ArticleDOI

DEGRO practical guidelines: radiotherapy of breast cancer III--radiotherapy of the lymphatic pathways.

TL;DR: Recent data suggest that the current restrictive use of RNI should be scrutinized because the risk–benefit relationship appears to shift towards an improvement of outcome.
Journal ArticleDOI

Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.

TL;DR: Afatinib dosage does not affect clinical efficacy and drug-related side effects, and patients with brain metastases had a poorer Eastern Cooperative Oncology Group performance status and were associated with a shorter median progression-free survival.
Related Papers (5)